BOSTON and SAN DIEGO — November 11, 2025 — Leads & Copy — SOPHiA GENETICS and Element Biosciences have partnered to integrate sequencing and AI analytics, streamlining genomic workflows and accelerating precision medicine research. The announcement was made today at the Association for Molecular Pathology (AMP) Annual Meeting.
The collaboration combines SOPHiA GENETICS’ AI-powered SOPHiA DDM™ analytics platform with Element’s AVITI24™ 5D multiomic and AVITI™ sequencing systems. The goal is to deliver a seamless, end-to-end workflow for next-generation sequencing (NGS).
According to the companies, the integrated technologies will provide researchers with speed, scalability, and flexibility, enabling them to transform NGS data into actionable insights through a single, streamlined process. AVITI and AVITI24 users will also gain access to SOPHiA DDM™ applications in oncology and rare diseases, enhancing the analytical capabilities of their sequencing workflows.
Professor Hagay Sobol, Head of the Molecular Oncogenetics Laboratory at the Institut Paoli-Calmettes (IPC), believes the combination of Element’s AVITI system and SOPHiA DDM™ Platform can transform genomic testing by delivering highly accurate results. Sobol anticipates the partnership will provide the consistency and scalability needed to advance precision medicine.
IPC, located in Marseille, France, is a comprehensive cancer center specializing in cancer research, treatment, and teaching.
Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS, stated that integrating their universal platform with technologies like the Element AVITI system will allow healthcare organizations to adopt AI-driven technologies while keeping genomic research local. Camblong said the partnership aligns with the shared goal of democratizing access to research supporting precision medicine globally.
Molly He, CEO and Co-Founder of Element Biosciences, said that pairing Element’s AVITI and AVITI24 systems with SOPHiA GENETICS’ AI analytics is a “game-changer” for the genomics community. He added that the collaboration redefines the possibilities in sequencing, delivering richer insights, faster results, and unprecedented accessibility.
SOPHiA DDM™ is a technology-agnostic analytics platform that uses AI to compute, standardize, and analyze healthcare data. SOPHiA GENETICS says it is committed to ensuring compatibility across all technologies, allowing laboratories to process datasets of any size, retain data control, and scale efficiently.
Element Biosciences’ AVITI24 5D Multiomic and AVITI next-generation sequencing systems are designed to make high-performance genomics accessible. Element says its combination of accuracy, flexibility and cost efficiency empowers laboratories to scale confidently and accelerate the research driving precision medicine worldwide.
To learn more about the partnership or SOPHiA GENETICS, visit booth 921 at AMP in Boston, Massachusetts, from November 11 – 15 or visit SOPHiAGENETICS.com.
SOPHiA DDM™ is for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
Contact support@sophiagenetics.com for further inquiries.
